INTERNATIONAL STEM CELL CORPORATION (OTCMKTS:ISCO) Files An 8-K Unregistered Sales of Equity SecuritiesITEM 3.02 Unregistered Sales of Equity Securities
On November 14, 2016, International Stem Cell Corporation (the “Company”) filed its Quarterly Report on Form 10-Q for the period ended September 30, 2016 (the “November Quarterly Report”) reporting 3,642,696 shares outstanding as of November 12, 2016.
On December 8, 2016, the Company issued an additional 285,714 shares of common stock in a transaction that was not registered under the Securities Act of 1933, resulting in an increase in the number of shares of common stock outstanding by more than 5% compared to the number of shares last updated in the November Quarterly Report. The Company issued 285,714 shares to Dr. Andrey Semechkin upon the exercise for cash of his Series C Warrants issued in the financing transaction completed in March 2016. The Company received total consideration of approximately $500,000 upon exercise of those warrants. The shares of common stock issued upon exercise of those warrants were issued in a private transaction in reliance upon the exemption from registration in Section 4(a)(2) of the Securities Act of 1933. Dr. Andrey Semechkin is the Company’s Co-Chairman and Chief Executive Officer. Reflecting these issuances, as of December 8, 2016, the Company had 3,928,410 shares of common stock outstanding.
About INTERNATIONAL STEM CELL CORPORATION (OTCMKTS:ISCO)
International Stem Cell Corporation (ISCO) is a biotechnology company. The Company is focused on therapeutic and biomedical product development. The Company’s segments include Therapeutic Market, Cosmetic Market and Biomedical Market. The Company’s subsidiaries include International Stem Cell Corporation, a research and development company, for the Therapeutic Market for clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases, such as Parkinson’s disease, liver diseases and corneal blindness; Cyto Therapeutics, PTY LTD, a research and development company, for the Therapeutic Market; Lifeline Skin Care, Inc. for the Cosmetic Market, which develops, manufactures and markets a category of cosmetic skin care products based on biotechnology with human stem cells, and Lifeline Cell Technology, LLC for the Biomedical Market, which develops, manufactures and commercializes primary human cell research products. INTERNATIONAL STEM CELL CORPORATION (OTCMKTS:ISCO) Recent Trading Information
INTERNATIONAL STEM CELL CORPORATION (OTCMKTS:ISCO) closed its last trading session up +0.02 at 1.35 with 12,977 shares trading hands.